Consensus $737.15M. Raises FY25 gross margin view to 80%-82% from 78%-80%.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PCRX:
- Pacira concludes patient enrollment in Part A of Phase 2 study of PCRX-201
- Pacira enters exclusive license, collaboration agreement with AmacaThera
- Pacira presents updated three-year results of PCRX-201
- Pacira (PCRX) Q3 Earnings Cheat Sheet
- Pacira’s Pediatric Analgesia Study: A Potential Game-Changer for Postoperative Pain Management